Approximately 7.5 million people in the U.S., and a 125 million worldwide, have psoriasis, an immune-mediated skin disorder that presents with different symptoms and severities. Characterized by raised and inflamed patches of skin, often on the elbows, knees, scalp, hands and feet, psoriasis causes itching, irritation, stinging and pain. And if left untreated, it can lead to serious medical complications, such as: ischemic heart disease, abdominal aneurysms, stroke, hypertension, diabetes and Crohn’s disease.
A recent “Psoriasis in America” 2016 survey of 582 individuals living with psoriasis details how difficult managing the condition—for which there is yet no known cure—can be. While various treatments exist, from topical medications, phototherapy and systemic drugs, including costly biologics (far from affordable) often associated with serious side effects, many psoriasis sufferers are frustrated by inadequacies in the care they receive.
The above findings mirror those of the National Psoriasis Foundation, which, from 2003-2011, surveyed over 5,600 individuals, revealing almost three-in-four people with mild or moderate psoriasis are off-treatment altogether. For people with psoriasis who do receive treatment, almost half, regardless of disease severity, express dissatisfaction with the clinical management of their psoriasis.
Feeling undertreated, these patients are more likely switch therapies more often, experiencing additional disruptions in continuity of care—reinforcing the need for easier-to-administer, safe, and effective drugs, so as to better ensure improved patient adoption and continuing treatment compliance.
Cellceutix is developing Prurisol as an oral psoriasis medication and hopes eventually it will offer patients another safe and effective therapeutic option in treating this serious and extremely hard-to-manage condition.